Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
This article was originally published in The Pink Sheet Daily
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.
You may also be interested in...
Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
Long-time Warburg Pincus investor Jonathan Leff is making a move to Deerfield Management. He tells “The Pink Sheet” about his plans and contemplates what’s next for investment in private biotechs.